Overview

Chemotherapy Induction and Chemoradiotherapy in Patients With Esophageal Carcinoma

Status:
Terminated
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The aim of this study is the evaluate the feasibility and safety of chemotherapy induction treatment combined with cetuximab followed by chemoradiotherapy combined with cetuximab in the treatment of patients with non-metastatic esophageal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Arbeitsgemeinschaft medikamentoese Tumortherapie
Collaborators:
Merck Sharp & Dohme Corp.
Sanofi
Treatments:
Cetuximab
Docetaxel